Thacharodi Aswin, Vithlani Avadh, Hassan Saqib, Alqahtani Ali, Pugazhendhi Arivalagan
Dr. Thacharodi's Laboratories, Department of Research and Development, Puducherry 605005, India.
Senior Resident, Department of Pulmonary Medicine, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India.
iScience. 2024 Nov 12;27(12):111367. doi: 10.1016/j.isci.2024.111367. eCollection 2024 Dec 20.
Carbapenem-resistant (CRAB) is a top-priority pathogen causing a nosocomial infection that increases morbidity and mortality. Treatment options for CRAB are relatively limited by pharmacokinetic restrictions, such as substantial toxicity. Therefore, we must better understand this pathogen to develop new treatments and control strategies. The review aims to provide an overview of the current understanding of acquired, adaptive, and intrinsic Carbapenem-resistant pathways in , as well as its consequences on healthcare systems, particularly critical care units. The review also provides insights into how CRAB infections are currently managed worldwide and why novel therapeutic regimens are needed. The peculiarity of and its often reported virulence factors have been discussed further. In conclusion, the purpose of this review is to emphasize the current knowledge on CRAB, as it causes major worry in the field of nosocomial infections as well as overall public health.
耐碳青霉烯类鲍曼不动杆菌（CRAB）是导致医院感染的重点病原体，会增加发病率和死亡率。由于药代动力学限制，如毒性大，CRAB的治疗选择相对有限。因此，我们必须更好地了解这种病原体，以开发新的治疗方法和控制策略。本综述旨在概述目前对CRAB获得性、适应性和固有性耐碳青霉烯类途径的理解，以及其对医疗系统，特别是重症监护病房的影响。该综述还深入探讨了目前全球如何管理CRAB感染以及为何需要新的治疗方案。进一步讨论了CRAB的特性及其经常报道的毒力因子。总之，本综述的目的是强调目前关于CRAB的知识，因为它在医院感染领域以及整体公共卫生方面引起了重大担忧。
